Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?

Eurosurveillance

Volumn 21, Issue 19, 2016, Pages

  Hope, Vivian D ^a,b   Cullen, K J ^a   Smith, J ^c   Jessop, L ^d   Parry, J ^a,b   Ncube, F ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

^d PUBLIC HEALTH AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4' METHYLMETHCATHINONE; AMPHETAMINE; COCAINE; DIAMORPHINE; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; OPIATE; CENTRAL STIMULANT AGENT; METHAMPHETAMINE;

ADULT; AGE; ARTICLE; AWARENESS; BLOOD BORNE VIRUS INFECTION; CONDOM USE; DRIED BLOOD SPOT TESTING; DRUG MISUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HIGH RISK BEHAVIOR; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTOXICATION; MALE; OPIATE SUBSTITUTION TREATMENT; QUESTIONNAIRE; SEXUAL HEALTH; UNITED KINGDOM; VIRUS INFECTION; WESTERN BLOTTING; AGE DISTRIBUTION; ANALOGS AND DERIVATIVES; BLOODBORNE BACTERIUM; CAUSALITY; COMMUNICABLE DISEASES, EMERGING; COMORBIDITY; DRUG USE; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; NEEDLE SHARING; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VIREMIA; VIROLOGY; VULNERABLE POPULATION;

ADULT; AGE DISTRIBUTION; BLOOD-BORNE PATHOGENS; CAUSALITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMMUNICABLE DISEASES, EMERGING; COMORBIDITY; DRUG USERS; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; NEEDLE SHARING; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED KINGDOM; VIREMIA; VULNERABLE POPULATIONS;

EID: 85015355230     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.19.30225     Document Type: Article

References (43)

1. Europol-European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). Lisbon: EMCDDA; March 2010. Available from: www. emcdda. europa. eu/html. cfm/index132196EN. html
2. Winstock AR, Ramsey JD. Legal highs and the challenges for policy makers. Addiction. 2010; 105(10): 1685-7. Available from: DOI: 10. 1111/j. 1360-0443. 2010. 02934. x PMID: 20840205
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Responding to new psychoactive substances. Drugs in focus (ISSN 1681-5157). Lisbon: EMCDDA; 2011.
4. Musshoff F, Hottmann L, Hess C, Madea B. ["Legal highs" from the German internet-"bath salt drugs" on the rise]. Arch Kriminol. 2013; 232(3-4): 91-103. German. PMID: 24358620
5. German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014; 97(1): 2-8. Available from: DOI: 10. 1016/j. lfs. 2013. 07. 023 PMID: 23911668
6. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol. 2012; 32(5): 710-4. Available from: DOI: 10. 1097/JCP. 0b013e318266c70c PMID: 22926609
7. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011; 106(11): 1991-6. Available from: DOI: 10. 1111/j. 1360-0443. 2011. 03502. x PMID: 21592252
8. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl). 2011; 214(3): 593-602. Available from: DOI: 10. 1007/s00213-010-2070-x PMID: 21072502
9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Injection of synthetic cathinones in Europe. Perspectives on Drugs series. Lisbon: EMCCDA; May 2014. Available from; www. emcdda. europa. eu/attachements. cfm/ att_228233_EN_POD2014_Injection%20of%20synthetic%20 cathinones. pdf
10. Peterfi A, Tarjan A, Horvath GC, Csesztregi T, Nyirady A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal. 2014; 6(7-8): 825-31. Available from: DOI: 10. 1002/dta. 1625 PMID: 24692417
11. Oprea C, Ceausu E, Ruta S. Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. Public Health. 2013; 127(11): 1048-50. Available from: DOI: 10. 1016/j. puhe. 2013. 08. 018 PMID: 24239282
12. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet. 2013; 381(9861): 101-2. Available from: DOI: 10. 1016/S0140-6736(13)60032-X PMID: 23320280
13. Peyriere H, Jacquet JM, Eiden C, Tuaillon E, Psomas C, Reynes J. Viral and bacterial risks associated with mephedrone abuse in HIV-infected men who have sex with men. AIDS. 2013; 27(18): 2971-2. Available from: DOI: 10. 1097/ QAD. 0000000000000029 PMID: 25119693
14. Kelly BC, Wells BE, Pawson M, Leclair A, Parsons JT, Golub SA. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013; 32(6): 588-93. Available from: DOI: 10. 1111/dar. 12058 PMID: 23795887
15. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)-Europol 2008 annual report on the implementation of Council Decision 2005/387/JHA. Lisbon: EMCDDA; May 2009. Available from: www. emcdda. europa. eu/html. cfm/ index132901EN. html
16. Advisory Council on the Misuse of Drugs (ACMD). Consideration of cathinones. London: ACMD; 2010.
17. A change to the misuse of drugs act 1971: control of mephedrone and other cathinone derivatives. London: Home Office; April 2010. Available from: http: //webarchive. nationalarchives. gov. uk/20130125102358/http: //www. homeoffice. gov. uk/about-us/corporate-publications-strategy/ home-office-circulars/circulars-2010/010-2010/
18. Daly M. 'Drone strikes. Druglink. 2012; 27(6): 8-11. Available from: http: //www. drugwise. org. uk/wp-content/uploads/ Druglink-Nov-Dec-2012. pdf
19. Van Hout MC, Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy. 2012; 23(3): 188-97. Available from: DOI: 10. 1016/j. drugpo. 2012. 01. 008 PMID: 22342322
20. Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, et al. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS. 2005; 19(11): 1207-14. Available from: DOI: 10. 1097/01. aids. 0000176222. 71355. a1 PMID: 15990575
21. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, et al. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol. 2009; 170(3): 352-60. Available from: DOI: 10. 1093/ aje/kwp141 PMID: 19546152
22. Connell JA, Parry JV, Mortimer PP, Duncan J. Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine. J Med Virol. 1993; 41(2): 159-64. Available from: DOI: 10. 1002/jmv. 1890410212 PMID: 8283178
23. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol. 2003; 71(1): 49-55. Available from: DOI: 10. 1002/jmv. 10463 PMID: 12858408
24. Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect. 2014; 143(7): 1398-407. PMID: 25119383
25. Judd A, Hickman M, Hope VD, Sutton AJ, Stimson GV, Ramsay ME, et al. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat. 2007; 14(8): 584-91. Available from: DOI: 10. 1111/j. 1365-2893. 2007. 00844. x PMID: 17650293
26. Powis B, Strang J, Griffiths P, Taylor C, Williamson S, Fountain J, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction. 1999; 94(4): 471-8. Available from: DOI: 10. 1046/j. 1360-0443. 1999. 9444712. x PMID: 10605843
27. Business as usual? A status report on new psychoactive substsances (NPS) and 'club drugs' in the UK. London: Drugscope; 2014. Available from: http: //www. drugwise. org. uk/wp-content/uploads/businessasusual. pdf
28. UK Focal Pont at Public Health England. United Kingdom drug situation: Annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2013. Davies C, Murray R, eds. London: Public Health England; October 2013. Available from: www. nta. nhs. uk/uploads/24780focalpointreport2013. pdf
29. Hay G, Rael dos Santos A, Worsley J. Estimates of the prevalence of opiate use and/or crack cocaine use, 2011/12: Sweep 8 report. Liverpool: John Moores University; April 2014. Available from: www. nta. nhs. uk/facts-prevalence. aspx
30. UK Focal Pont at Public Health England. United Kingdom drug situation: Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2009. Davies C, English L, Lodwick A, McVeigh J, Bellis, M, eds. London: Public Health England; October 2009. Available from: http: //www. nta. nhs. uk/uploads/2009. pdf
31. Public Health England, Health Protection Scotland, Public Health Wales, and Public Health Agency Northern Ireland. Shooting Up: Infections among people who inject drugs in the United Kingdom 2013. London: Public Health England, November 2014. Available from: https: //www. gov. uk/ government/uploads/system/uploads/attachment_data/ file/370707/Shooting_Up_2014. pdf
32. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. outbreak control team. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveill. 2015; 20(40): 30036. Available from: DOI: 10. 2807/1560-7917. ES. 2015. 20. 40. 30036 PMID: 26537764
33. Gilbart VL, Simms I, Gobin M, Oliver I, Hughes G. Highrisk drug practices in men who have sex with men. Lancet. 2013; 381(9875): 1358-9. Available from: DOI: 10. 1016/S0140-6736(13)60882-X PMID: 23601946
34. Simms I, Gilbart VL, Byrne L, Jenkins C, Adak GK, Hughes G, et al. Identification of verocytotoxin-producing Escherichia coli O117: H7 in men who have sex with men, England, November 2013 to August 2014. Euro Surveill. 2014; 19(43): 20946. Available from: DOI: 10. 2807/1560-7917. ES2014. 19. 43. 20946 PMID: 25375900
35. Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark & Lewisham. London: Sigma Research, London School of Hygiene and Tropical Medicine; 2014.
36. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014; 25(1): 34-52. Available from: DOI: 10. 1016/j. drugpo. 2013. 07. 001 PMID: 23973009
37. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health and devolved administrations, 2007. Available from: www. nta. nhs. uk/ uploads/clinical_guidelines_2007. pdf
38. European Centre for Disease Prevention and Control (ECDC). Mapping of HIV/STI behavioural surveillance in Europe. ECDC Technical Report. Stockholm: ECDC; September 2009. Available from: http: //www. ecdc. europa. eu/en/publications/ Publications/0909_TER_Mapping_of_HIV_STI_Behavioural_ Surveillance_in_Europe. pdf
39. Topp L, Iversen J, Wand H, Day C, Kaldor J, Maher L, Collaboration of Australian Needle Syringe Programs. Representativeness of injecting drug users who participate in HIV surveillance: results from Australia's Needle and Syringe Program Survey. J Acquir Immune Defic Syndr. 2008; 47(5): 632-8. Available from: DOI: 10. 1097/QAI. 0b013e31816a1d68 PMID: 18491422
40. Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007; 14(9): 645-52. Available from: DOI: 10. 1111/j. 1365-2893. 2007. 00855. x PMID: 17697017
41. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993; 88(4): 517-26. Available from: DOI: 10. 1111/j. 1360-0443. 1993. tb02058. x PMID: 8485429
42. De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol. 1996; 143(7): 725-32. Available from: DOI: 10. 1093/ oxfordjournals. aje. a008806 PMID: 8651235
43. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report: trends and developments. Lisbon: EMCDDA; June 2015. Available from: www. emcdda. europa. eu/publications/edr/trends-developments/2015